Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Clinical trial NCT02110563 · TERMINATED
Trial details
- NCT number
- NCT02110563
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2016-10-05
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.